Radiopharmaceutical Imaging And Dosimetry, LLC

Baltimore, MD

UEI
CM3LK9281JS7
CAGE
7L1Q8
Primary NAICS
541990 All Other Professional, Scientific, and Technical Services
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
1800 Gough St, Baltimore, MD 21231, USA
Industry
  1. Industrials
  2. Commercial & Professional Services
  3. Professional Services
SIC code
89 Services, Not Elsewhere Classified
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Sbir phase i topic 392: targeted radionuclide therapy of metastatic liver cancer: patient specific optimization 75N91019C00047 National Cancer Institute (NIH) $299,275
Topic 368: treatment optimization by combined a-emitter (arpt)/radiotherapy (XRT) dosimetry for prostate cancer patients 75N91019C00040 National Cancer Institute (NIH) $1,999,796
Sbir topic 368: user-friendly, platform-independent software will be developed to incorporate validated, in vivo… HHSN261201700038C National Cancer Institute (NIH) $299,466

Grant awards

Award Agency Obligated Awarded
Cloud/web-based platform for quantitative spect reconstruction of therapeutic radionuclides R44CA291419 National Cancer Institute (NIH) $1,003,173
Cloud/subscription based, customer-responsive dosimetry tool for alpha-particle emitters - direct to phase 2 sbir… R44CA291420 National Cancer Institute (NIH) $1,648,103
Development and validation of a collaborative web/cloud-based dosimetry system for radiopharmaceutical therapy. R44CA213782 National Cancer Institute (NIH) $3,412,033
Quantitative spect of difficult to image therapeutic radionuclides: an extensible cloud-based framework R43CA228776 National Cancer Institute (NIH) $299,995
Cloud/subscription based, customer-responsive dosimetry tool for alpha-particle emitters R43CA224643 National Cancer Institute (NIH) $293,774

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
The Johns Hopkins University Imaging, Dosimetry and Radiobiology for α-particle Emitter Radiopharmaceutical Therapy P01CA272222 $487,905
The Johns Hopkins University Combination Radiopharmaceutical Therapy and External Beam Radiotherapy R01CA240779 $781,458
The Johns Hopkins University High Energy and Spatial Resolution Multi-Isotope SPECT Imaging of Targeted Alpha-Emitters and their Daughters U01EB031798 $392,511
The Johns Hopkins University Hyperspectral Single Photon Imaging of Targeted Alpha-Emitters R01EB031023 $275,598

Similar vendors

Vendor Location Primary NAICS
Oncospace Inc. UEI HSG5CY5VWW33 — 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Doseoptics LLC UEI QERKPUEMGKH3 Lebanon, NH 334519 Other Measuring and Controlling Device Manufacturing
Quantitative Imaging Systems LLC UEI K5ELZZPK73V9 Pittsburgh, PA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Theracea Pharma LC UEI KSNLTEALRQL5 Tucson, AZ —
Collagen Medical LLC UEI GJLBDQT8K757 Boston, MA 325412 Pharmaceutical Preparation Manufacturing

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Radiopharmaceutical Imaging And Dosimetry, LLC is a for-profit limited liability company based in Baltimore, Maryland, registered in the System for Award Management (SAM) since March 2016. The company specializes in developing advanced software and technical solutions for medical imaging and dosimetry, with a primary focus on radiopharmaceutical therapy and cancer treatment research. Its core competencies center on creating innovative cloud-based platforms and software systems that enable precise quantitative imaging and dosimetry for emerging radiopharmaceutical therapies, particularly those utilizing alpha-emitting radionuclides.

The company has secured two significant federal grant awards from the National Cancer Institute, totaling approximately $1.9 million, to develop sophisticated cloud-based dosimetry and imaging technologies. These grants, awarded under the Cancer Treatment Research and Cancer Cause and Prevention Research programs, focus on creating a web/cloud-based quantitative SPECT reconstruction software system and a customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The company has also received multiple sub-grant awards from Johns Hopkins University, collaborating on projects related to imaging, dosimetry, and radiobiology for targeted alpha-emitter therapies. These grants involve developing advanced methodologies such as macro-to-micro dosimetry, creating libraries of microscale S-values, implementing computational techniques for assessing normal tissue toxicity, and developing educational materials for alpha-emitter dosimetry practitioners and regulatory authorities. The work demonstrates a strategic approach to advancing precision medicine techniques in cancer treatment through innovative software and computational solutions.

Quick answers

Is Radiopharmaceutical Imaging And Dosimetry, LLC registered in SAM.gov?

Yes. Radiopharmaceutical Imaging And Dosimetry, LLC's SAM.gov registration is active through September 15, 2027.

What is Radiopharmaceutical Imaging And Dosimetry, LLC's most recent federal award?

Radiopharmaceutical Imaging And Dosimetry, LLC's most recent federal grant award is Cloud/web-based platform for quantitative spect reconstruction of therapeutic radionuclides (R44CA291419), from National Cancer Institute (NIH), on February 1, 2025.

On GovTribe

See Radiopharmaceutical Imaging And Dosimetry, LLC's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login